We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Rubella Vaccine Trials in Adults and Children Comparison of Three Attenuated Vaccines

J. Alastair Dudgeon, MD; William C. Marshall, MB, BS; Catherine S. Peckham, MB, BS
Am J Dis Child. 1969;118(2):237-242. doi:10.1001/archpedi.1969.02100040239015.
Text Size: A A A
Published online


THE EVENTS of the past six years have made clear the need for prophylactic measures against rubella. In 1966, Parkman and Meyer and their colleagues1,2 reported the development of a live rubella vaccine which had been attenuated by passage in African green monkey kidney cultures. Clinical trials in susceptible children showed that the vaccine strain was immunogenic and produced very few reactions. Although virus excretion occurred in a proportion of the vaccinees, no transmission of infection was detected in susceptible contacts. Recently, further attenuated vaccines have been developed in different cell substrates,3 and, on account of the potential risk of nasopharyngeal excretion to pregnant women, most of the trials have so far been carried out in children in enclosed communities. Until more is known about the length of immunity from rubella vaccines, no firm decision can be made on the proper age for immunization against rubella. We therefore


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.